Liver-only metastatic colorectal cancer patients and thymidylate synthase polymorphisms for predicting response to 5-fluorouracil-based chemotherapy

[1]  V. Catalano,et al.  Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy , 2008, The Pharmacogenomics Journal.

[2]  Kai-huan Yu,et al.  Polymorphism of thymidylate synthase gene associated with its protein expression in human colon cancer. , 2008, World journal of gastroenterology.

[3]  D. Sargent,et al.  Patient characteristics and stratification in medical treatment studies for metastatic colorectal cancer: a proposal for standardization of patient characteristic reporting and stratification. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  F. Innocenti,et al.  Translation of pharmacogenetic knowledge into cancer therapeutics. , 2007, Clinical advances in hematology & oncology : H&O.

[5]  G. Peters,et al.  Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression after administration of 5‐fluorouracil to patients with colorectal cancer , 2007, International journal of cancer.

[6]  R. Labianca,et al.  Neoadjuvant chemotherapy for patients with liver metastases from colorectal cancer , 2007, Expert review of anticancer therapy.

[7]  V. Catalano,et al.  Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  A. Abad,et al.  Combined analysis of genetic polymorphisms in thymidylate synthase, uridine diphosphate glucoronosyltransferase and X-ray cross complementing factor 1 genes as a prognostic factor in advanced colorectal cancer patients treated with 5-fluorouracil plus oxaliplatin or irinotecan. , 2007, Oncology reports.

[9]  Sharon Marsh,et al.  Thymidylate synthase pharmacogenetics , 2005, Investigational New Drugs.

[10]  F. Cianchi,et al.  Relationships between promoter polymorphisms in the thymidylate synthase gene and mRNA levels in colorectal cancers. , 2005, European journal of cancer.

[11]  C. Köhne,et al.  Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  M. Valerio,et al.  Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  T. Maekawa,et al.  Effects on DNA and RNA after the administration of two different schedules of 5-fluorouracil in colorectal cancer patients , 2005, Cancer Chemotherapy and Pharmacology.

[14]  Yoshiro Saito,et al.  Polymorphic tandem repeat sequences of the thymidylate synthase gene correlates with cellular-based sensitivity to fluoropyrimidine antitumor agents , 2005, Cancer Chemotherapy and Pharmacology.

[15]  A. Jakobsen,et al.  Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  M. Baiget,et al.  Single nucleotide polymorphism in the 5′ tandem repeat sequences of thymidylate synthase gene predicts for response to fluorouracil‐based chemotherapy in advanced colorectal cancer patients , 2004, International journal of cancer.

[17]  G. Dardanoni,et al.  Thymidylate synthase gene promoter polymorphisms are associated with TSmRNA expressions but not with microsatellite instability in colorectal cancer. , 2004, Anticancer research.

[18]  D. Tregouet,et al.  Thymidylate Synthase Gene Polymorphism Predicts Toxicity in Colorectal Cancer Patients Receiving 5-Fluorouracil-based Chemotherapy , 2004, Clinical Cancer Research.

[19]  S. Groshen,et al.  A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer , 2004, British Journal of Cancer.

[20]  S. Groshen,et al.  A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. , 2004, Pharmacogenetics.

[21]  A. Matakidou,et al.  Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  K. Hayashi,et al.  Loss of Heterozygosity at the Thymidylate Synthase (TS) Locus on Chromosome 18 Affects Tumor Response and Survival in Individuals Heterozygous for a 28-bp Polymorphism in the TS Gene , 2004, Clinical Cancer Research.

[23]  G. Watanabe,et al.  Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene. , 2003, Cancer research.

[24]  H. Lenz,et al.  A novel single nucleotide polymorphism within the 5' tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. , 2003, Cancer research.

[25]  G. Watanabe,et al.  Functional Polymorphism of the Thymidylate Synthase Gene in Colorectal Cancer Accompanied by Frequent Loss of Heterozygosity , 2002, Japanese journal of cancer research : Gann.

[26]  C. Lombard-Bohas,et al.  Assessment of tumour response to chemotherapy for metastatic colorectal cancer: accuracy of the RECIST criteria. , 2002, The British journal of radiology.

[27]  N. Magné,et al.  Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  W. Scheithauer,et al.  Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  K. Hayashi,et al.  Changes in intratumoral thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) mRNA expression in colorectal and gastric cancer during continuous tegafur infusion. , 2001, International journal of oncology.

[30]  C. Ulrich,et al.  Searching expressed sequence tag databases: discovery and confirmation of a common polymorphism in the thymidylate synthase gene. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[31]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[32]  K. Kawakami,et al.  Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers. , 1999, Anticancer research.

[33]  N. Horie,et al.  Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5'-terminal regulatory region of the human gene for thymidylate synthase. , 1995, Cell structure and function.

[34]  S. Groshen,et al.  Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer , 2002, International Journal of Colorectal Disease.

[35]  S. Groshen,et al.  Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy , 2001, The Pharmacogenomics Journal.

[36]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[37]  R. Kath,et al.  [Tumor progression and metastasis]. , 1990, Zentralblatt fur Chirurgie.